SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
Valuing multistage investment projects in the pharmaceutical industry
16 references·0 citing·53 second hop
Valuing multistage investment projects in the pharmaceutical industry (2018)Valuing multistage investment projects in…Innovation in the pharmaceutical industry: New estimates of R&D costs (2016)Innovation in the pharmaceuti…Product market competition, R&D investment, and stock returns (2015)Product market competition, R…Quality uncertainty and quality-compensation contract for supply chain coordination (2013)Quality uncertainty and quali…Evaluating pharmaceutical R&D under technical and economic uncertainty (2011)Evaluating pharmaceutical R&D…Capabilities and financial performance: the moderating effect of strategic type (2007)Capabilities and financial pe…R&D Investments with Competitive Interactions (2004)R&D Investments with Competit…Patents and R&D as Real Options (2004)Patents and R&D as Real Optio…Valuation and Return Dynamics of New Ventures (2003)Valuation and Return Dynamics…The valuation of a NDA using a 6-fold compound option (2003)The valuation of a NDA using …Valuing American Options by Simulation: A Simple Least-Squares Approach (2001)Valuing American Options by S…Rational Pricing of Internet Companies Revisited (2001)Rational Pricing of Internet …Evaluating growth options as sources of value for pharmaceutical research projects (2001)Evaluating growth options as …Research and Development Costs for New Drugs by Therapeutic Category (1995)Research and Development Cost…Investments of uncertain cost (1993)Investments of uncertain costTime to build, option value, and investment decisions (1987)Time to build, option value, …The valuation of compound options (1979)The valuation of compound opt…The Theory of Industrial Organization (1988)The Cross-Section of Expected Stock Returns (1992)On Persistence in Mutual Fund Performance (1997)Do women managers keep firms out of trouble? Evidence from corporate litigation and policies (2018)Digital Financial Inclusion and Sustainable Growth of Small and Micro Enterprises—Evidence Based on China’s New Third Board Market Listed Companies (2020)Does mixed-ownership reform improve SOEs' innovation? Evidence from state ownership (2020)The Pricing of Options and Corporate Liabilities (1973)Theory of Rational Option Pricing (1973)Determinants of corporate borrowing (1977)Option values under stochastic volatility: Theory and empirical estimates (1987)THE GARCH OPTION PRICING MODEL (1995)Arbitrage Theory in Continuous Time (2004)A Coefficient of Agreement for Nominal Scales (1960)A resource‐based view of the firm (1984)Structural equation modeling in practice: A review and recommended two-step approach. (1988)You can’t manage right what you can’t measure well: Technological innovation efficiency (2013)Circular economy practices and industry 4.0 technologies: A strategic move of automobile industry (2021)Marketing in the Metaverse: Conceptual understanding, framework, and research agenda (2022)A New Look at the Returns and Risks to Pharmaceutical R&D (1990)Cost of innovation in the pharmaceutical industry (1991)The Size Distribution of Profits from Innovation (1998)New Drug Innovation and Pharmaceutical Industry Structure: Trends in the Output of Pharmaceutical Firms (2000)R&D Costs and Returns by Therapeutic Category (2004)Regression methods for pricing complex American-style options (2001)New frontiers for arch models (2002)Option Pricing Under a Double Exponential Jump Diffusion Model (2004)Theory of rational option pricing (2005)Cost-Effectiveness in Health and Medicine (1996)The price of innovation: new estimates of drug development costs (2003)How to improve R&D productivity: the pharmaceutical industry's grand challenge (2010)Essential medicines for universal health coverage (2016)The High Cost of Prescription Drugs in the United States (2016)Estimated Research and Development Investment Needed to Bring a New Medicine to Market, 2009-2018 (2020)The Value of Waiting to Invest (1982)Irreversibility, Uncertainty, and Investment (1990)Investment and Hysteresis (1992)Effects of Air Quality Regulation on in Polluting Industries (1997)Investment under market and climate policy uncertainty (2008)Climate Regulatory Risk and Corporate Bonds (2022)An Intertemporal Capital Asset Pricing Model (1973)Investment under Uncertainty (1994)Investment Under Uncertainty. (1994)Uncertainty and the Dynamics of R&D (2007)A real options–based CCS investment evaluation model: Case study of China’s power generation sector (2011)A novel modeling based real option approach for CCS investment evaluation under multiple uncertainties (2013)Patents as Options: Some Estimates of the Value of Holding European Patent Stocks (1984)Patents as Options: Some Estimates of the Value of Holding European Patent Stocks (1986)Real Options, Product Market Competition, and Asset Returns (2009)Risk and Return Characteristics of Venture Capital-Backed Entrepreneurial Companies (2010)Time to Build and Aggregate Fluctuations (1982)Option Valuation of Claims on Real Assets: The Case of Offshore Petroleum Leases (1988)Real Options and Interactions with Financial Flexibility (1993)Strategy through the Option Lens: An Integrated View of Resource Investments and the Incremental-Choice Process (1993)
this work references cited by second hop

References

  • 2016Innovation in the pharmaceutical industry: New estimates of R&D costs3,352 cited
  • 2001Valuing American Options by Simulation: A Simple Least-Squares Approach3,218 cited
  • 1979The valuation of compound options1,107 cited
  • 1987Time to build, option value, and investment decisions912 cited
  • 1993Investments of uncertain cost480 cited
  • 2007Capabilities and financial performance: the moderating effect of strategic type315 cited
  • 2003Valuation and Return Dynamics of New Ventures311 cited
  • 2015Product market competition, R&D investment, and stock returns307 cited
  • 2004Patents and R&D as Real Options205 cited
  • 1995Research and Development Costs for New Drugs by Therapeutic Category169 cited
  • 2001Rational Pricing of Internet Companies Revisited133 cited
  • 2001Evaluating growth options as sources of value for pharmaceutical research projects113 cited
  • 2003The valuation of a NDA using a 6-fold compound option111 cited
  • 2011Evaluating pharmaceutical R&D under technical and economic uncertainty86 cited
  • 2004R&D Investments with Competitive Interactions73 cited
  • 2013

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work

Quality uncertainty and quality-compensation contract for supply chain coordination
72 cited

Cited by

No citing works inside the corpus for this window.